A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED March 19, 2021 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide updates as new… Read More »
VGXI Official Statement Regarding COVID-19
VGXI Completes Land Purchase and Advances Design Development for New Manufacturing Facility
Plasmid DNA Manufacturer VGXI, Inc. Completes Land Purchase and Proceeds with Design Development Phase for New Expanded Manufacturing Facility. The Woodlands, TX – VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has closed on the purchase of greenfield for a new, expanded manufacturing facility. The site is located… Read More »
VGXI to Exhibit at Gene Therapy for Rare Disorders
The 4th Annual Gene Therapy for Rare Disorders will focus on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. Visit VGXI at Booth #6 or meet with one of our representatives during the conference to learn more about how our plasmid manufacturing services can support your gene therapy program! Contact… Read More »
VGXI to Exhibit at the 2020 World Vaccine Congress
The World Vaccine Congress is a critical strategic partnering event for the global vaccine industry. Visit our Booth #310 or meet with a representative from VGXI during the conference in April to learn more about how our plasmid manufacturing services can support your vaccine program! Each year at WVC the winners are announced for the annual… Read More »
VGXI to Exhibit at the International HCV Symposium
The 26th International Symposium on Hepatitis C Virus and Related Viruses focuses on the advancement of HCV and related virus research, vaccines, and therapies. We welcome you to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn more about VGXI’s plasmid manufacturing services and experience! Contact Us directly to request… Read More »
VGXI to Exhibit at the Cell & Gene Meeting on the Mesa
The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. Be sure to stop by VGXI’s booth or schedule a meeting with one of our representatives during the conference to learn how VGXI’s plasmid manufacturing services… Read More »
Texas Based CMO VGXI and Geneos Therapeutics Establish Supply Agreement for Production of GT-EPIC-Based Personalized Cancer Therapeutics
Industry recognized plasmid DNA manufacturer VGXI, Inc. to support production of personalized cancer therapies as part of a long-term supply agreement with Geneos Therapeutics. June 22, 2019, The Woodlands, TX and Plymouth Meeting, PA – Plasmid CMO VGXI, Inc. and Geneos Therapeutics, Inc., a spin-out of Inovio Pharmaceuticals (NASDAQ: INO) focused on developing DNA-based, Neoantigen-targeting personalized… Read More »
VGXI to Exhibit at the 2019 BIO International Convention
With over 16,000 attendees, BIO is one of the largest biotech partnering, education, and networking events in the world. Be sure to stop by VGXI’s Booth #3349 or schedule a meeting with one of our representatives during the conference to learn how VGXI’s plasmid manufacturing services can support your gene or cell therapy program! Contact Us directly or use BIO’s One-On-One… Read More »
VGXI Celebrates Grand Opening of New Flex-Scale Production Plant for GMP
U.S. Congressman Kevin Brady visited Texas-based CMO VGXI to celebrate the grand opening of the company’s new flexible scale GMP production plant for DNA and RNA based therapeutics. VGXI, an industry recognized plasmid DNA contract manufacturing organization, announced the grand opening of a facility expansion which includes flexible scale plasmid DNA manufacturing space as well… Read More »
Meet VGXI at the AAV Gene Therapy Symposium
Meet with representatives from VGXI at the 2nd Annual AAV Gene Therapy Symposium on 10 December, 2018. We would welcome an opportunity to introduce ourselves and share information on VGXI’s customized plasmid DNA manufacturing solutions to support your AAV production needs. Contact Us today to request a meeting. 2018 AAV Gene Therapy Symposium 10 December, 2018 Bioscience… Read More »
Meet VGXI at the 2018 ASGCT Annual Meeting
Will you be attending the ASGCT 21st Annual Meeting in May, 2018? Meet with representatives from VGXI at Booth # 105 and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. ASGCT’s 21st Annual Meeting 16-19 May, 2018 Hilton Chicago
VGXI is a Finalist for BEST CMO at the 2018 ViE Awards!
As a leading GMP manufacturer of high quality plasmid DNA, VGXI, Inc. has been recognized in the final shortlist of companies for the category of “Best Contract Manufacturing Organization (CMO)” for the 2018 Vaccine Industry Excellence Awards. Click here to view the full list of finalists for the ViE Awards Will you be attending the World Vaccine Congress in… Read More »